Manager × security

RENAISSANCE GROUP LLC VRTX holdings history

Who else holds this security? →

VERTEX PHARMACEUTICALS INC · CUSIP 92532F100 · CIK 944234

This is the oldest quarter open without an account, so changes against the quarter before it are withheld. Sign in to see them.
Citable facts

As of 2026-06-30, RENAISSANCE GROUP LLC reported 1.01K VRTX (shares), valued at $500.62K, or 0.02% of its reported non-derivative portfolio. Filed 2026-08-13.

Verify history & sources →
Portfolio weight and quantity history
Reported portfolio weight
0.02%
Shares
1.01K
1,008
Reported value
$500.62K
USD

Shares decreased 5.97%; reported value increased 4.54%, and weight changed +0.00 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.

Left: % · Right: Shares · Independently scaled axes

Exact data and methodology

Axes scale independently; a crossing does not mean equal values. Weight uses each quarter's total reported non-derivative value. Same CUSIP; missing quarters are gaps, not zero. Revised history may include later disclosures.

QuarterWeightQuantitySource
Q2 20260.02%1,008SEC filing ↗Filed Aug 13, 2026
Q1 20260.02%1,072SEC filing ↗Filed May 13, 2026
Q4 20250.03%1,433SEC filing ↗Filed Feb 11, 2026
Q3 20250.02%1,468SEC filing ↗Filed Nov 5, 2025
Q2 20250.03%1,519SEC filing ↗Filed Aug 11, 2025
Q1 20250.04%1,714SEC filing ↗Filed May 13, 2025
Q4 20240.05%3,182SEC filing ↗Filed Feb 13, 2025
Q3 20240.06%3,224SEC filing ↗Filed Nov 12, 2024
Q2 20241.34%73,479SEC filing ↗Filed Aug 14, 2024
Q1 20241.23%77,696SEC filing ↗Filed Apr 26, 2024Combination report
Q4 20231.50%88,932SEC filing ↗Filed Feb 9, 2024Combination report
Q3 20231.47%92,271SEC filing ↗Filed Nov 13, 2023

History & evidence by quarter

QuarterWeightQuantityValueChange explainedSource
Q3 20231.47%92,271$32.09MThe prior quarter is outside the free window. Sign in for the comparison.SEC filing ↗
Filed Nov 13, 2023
Q4 20231.50%88,932$36.19MShares decreased 3.62%; reported value increased 12.79%, and weight changed +0.03 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Feb 9, 2024
Q1 20241.23%77,696$32.48MShares decreased 12.63%; reported value decreased 10.26%, and weight changed -0.27 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Apr 26, 2024
Q2 20241.34%73,479$34.44MShares decreased 5.43%; reported value increased 6.04%, and weight changed +0.11 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Aug 14, 2024
Q3 20240.06%3,224$1.50MShares decreased 95.61%; reported value decreased 95.65%, and weight changed -1.28 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Nov 12, 2024
Q4 20240.05%3,182$1.28MShares decreased 1.30%; reported value decreased 14.54%, and weight changed -0.01 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Feb 13, 2025
Q1 20250.04%1,714$830.93KShares decreased 46.13%; reported value decreased 35.16%, and weight changed -0.01 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed May 13, 2025
Q2 20250.03%1,519$676.31KShares decreased 11.38%; reported value decreased 18.61%, and weight changed -0.01 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Aug 11, 2025
Q3 20250.02%1,468$574.73KShares decreased 3.36%; reported value decreased 15.02%, and weight changed -0.01 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Nov 5, 2025
Q4 20250.03%1,433$649.59KShares decreased 2.38%; reported value increased 13.02%, and weight changed +0.01 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Feb 11, 2026
Q1 20260.02%1,072$478.85KShares decreased 25.19%; reported value decreased 26.28%, and weight changed -0.01 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed May 13, 2026
Q2 20260.02%1,008$500.62KShares decreased 5.97%; reported value increased 4.54%, and weight changed +0.00 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Aug 13, 2026
RENAISSANCE GROUP LLC · VERTEX PHARMACEUTICALS INC

Take these holdings further.

This page includes 12 of 12 reported holdings. Sign in to look up the full history beyond 3 years, use advanced screening & filtering, download CSV, and get the complete set through the Akkru API.

  • Download CSV
  • Earlier quarters
  • Advanced screening & filtering
  • API & AI access
Already have an account?

+ New accounts get free API credits to explore data beyond ownership filings.

For AI agents & developers

The initial HTML of this page carries its exact data as script#research-data (JSON): values, units, scope, preview limits and SEC sources. Read it directly, no script or API key needed; script#research-access says what needs an account.

Without an account: the last 3 years, with the row caps stated on the page. A free account opens all history on file on these pages and the CSV of what a page shows. Rows beyond the caps and bulk retrieval go through the authenticated API / MCP.

MCP  https://api.akkrudata.ai/mcp

get_institutional_portfolio
{"cik":"944234","quarter":"2026Q2","cusip":"92532F100"}

get_institutional_manager_history
{"cik":"944234","page_size":100}

Connect to MCP with OAuth and follow the returned pagination. Credits and usage limits depend on the account.

MCP endpoint
https://api.akkrudata.ai/mcp
API / MCP documentation
/documents
llms.txt
/llms.txt
Sources, coverage & how to read this data

Figures are as reported to the SEC and merged with later amendments where Akkru could match them. Preview limits apply to what is listed, not to the totals, which come from the complete reported data. Nothing is zero-filled: a missing quarter or month is shown as missing.

13F reports quarter-end long positions in securities traded on US exchanges, filed by managers holding at least $100 million of such securities; it is not the manager's full portfolio, not assets under management, and value changes are not returns. Weights use the reported total value as denominator. Option rows show notional value, not premium or net exposure. Amendments are merged into the quarter when Akkru could match them.